부산대학교 도서관

Anecortave acetate inhibits the growth of blood vessels present in choroidal neovascularization that are associated with exudative age-related macular degeneration independent of the inciting cause of angiogenesis. When anecortave acetate is administered as a posterior juxtascleral depot outside the eye, effective levels of the drug are delivered to the macula for 6 months. Anecortave acetate 15 mg has been shown to be efficacious at inhibiting vision loss and choroidal neovascularization lesion growth in a placebo-controlled, double-masked clinical trial in patients with exudative age-related macular degeneration. Depot administration is well suited for controlling active choroidal neovascularization, as well as suppressing choroidal neovascularization development. Finally, clinical studies have demonstrated that anecortave acetate has excellent ocular and systemic safety profiles.